. Author manuscript; available in PMC: 2015 Jun 18.

Published in final edited form as: Otolaryngol Head Neck Surg. 2014 Oct 30;152(1):23–41. doi: 10.1177/0194599814553930

Table 5.

Study Demonstrating a Statistically Significant Deleterious Effect of ASA on Pure-tone Thresholds or Speech Discrimination in Patients with Rheumatoid Arthritis and Connective Tissue Disorders.

Author, Year	Study Design (sample size)	Patient Description	ASA Regimen Evaluated	Hearing Evaluation	Follow-up Time	ASA Exposure Results	No ASA Exposure Results	Time from Exposure to Outcome	Additional Comments
Jardini, 1978³⁷	Randomized placebo-controlled study (n = 30)	All diagnosed with RA ASA: 13 women, 2 men Age 19–69 years (mean S3) Placebo: 14 women, 1 man Age 29–76 (mean 51)	ASA 325 mg (5 grain (1 grain = 65 mg) capsules) × 7 d (dosing frequency not specified) Lactose placebo × 7d	PT air/bone conduction thresholds at 250–8000 Hz SRT;SDS in quiet (recorded CID W-22) and in noise (−4 dB competing SNR)	Days 0, 3, and 7	ASA group had significantly increased PT threshold shifts at 250–8000 Hz except at 2000 Hz as compared to control (P < .05). ASA group had significantly poorer SRTs (P < .05). ASA group had significantly worse discrimination in background noise (P < .05).		Effect present at day 3	Moderate BSL (35 mg/100 mL) may adversely affect auditory sensitivity. Thresholds recovered over the course of 1 week.

Abbreviations: ASA, aspirin (acetylsalicylic acid); BSL blood serum level; CID W-22, word recognition list W-22 created by Central Institute for the Deaf; PT, pure tone; RA: rheumatoid arthritis; SDS, speech discrimination scores; SNR, signal to noise ratio; SRT, speech reception threshold.